Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:ASPCFNASDAQ:BFRINASDAQ:GNPXNASDAQ:INDP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASPCFAcerus Pharmaceuticals$0.22$0.22$0.22▼$8.16$1.70M0.691,500 shsN/ABFRIBiofrontera$0.72+5.3%$0.82$0.65▼$2.22$6.79M0.37915,394 shs252,410 shsGNPXGenprex$0.28+2.1%$0.30$0.22▼$4.09$6.81M-0.43.77 million shs660,221 shsINDPIndaptus Therapeutics$0.44+5.7%$0.56$0.36▼$3.10$7.06M1.49144,415 shs34,757 shs7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASPCFAcerus Pharmaceuticals0.00%0.00%0.00%0.00%0.00%BFRIBiofrontera-1.78%-2.50%-18.75%-37.39%-45.83%GNPXGenprex-3.26%-10.97%+3.56%-45.61%-88.10%INDPIndaptus Therapeutics+3.92%-9.70%-13.27%-48.30%-80.64%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationASPCFAcerus PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ABFRIBiofrontera2.9818 of 5 stars3.55.00.00.02.40.01.3GNPXGenprex4.148 of 5 stars3.52.00.04.73.40.01.3INDPIndaptus Therapeutics3.2829 of 5 stars3.55.00.00.02.01.71.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceASPCFAcerus Pharmaceuticals 0.00N/AN/AN/ABFRIBiofrontera 3.00Buy$7.00873.85% UpsideGNPXGenprex 3.00Buy$10.003,447.36% UpsideINDPIndaptus Therapeutics 3.00Buy$8.501,831.82% UpsideCurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookASPCFAcerus Pharmaceuticals$2.12M0.80N/AN/A($3.38) per share-0.07BFRIBiofrontera$37.32M0.18N/AN/A$3.16 per share0.23GNPXGenprexN/AN/AN/AN/A$4.99 per shareN/AINDPIndaptus TherapeuticsN/AN/AN/AN/A$1.44 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateASPCFAcerus Pharmaceuticals-$33.82M-$3.57N/A∞N/A-924.33%N/A-74.62%N/ABFRIBiofrontera-$20.13M-$2.26N/AN/AN/A-36.31%-565.73%-96.64%5/15/2025 (Estimated)GNPXGenprex-$30.86MN/A0.00N/AN/AN/A-409.48%-269.17%5/21/2025 (Estimated)INDPIndaptus Therapeutics-$15.42M-$1.62N/AN/AN/AN/A-177.27%-141.06%5/14/2025 (Estimated)Latest ASPCF, INDP, GNPX, and BFRI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/21/2025N/AGNPXGenprex-$0.82N/AN/AN/AN/AN/A5/15/2025Q1 2025BFRIBiofrontera-$0.14N/AN/AN/A$10.55 millionN/A5/14/2025N/AINDPIndaptus Therapeutics-$0.41N/AN/AN/AN/AN/A5/12/2025Q1 2025GNPXGenprex-$0.82-$0.26+$0.56-$0.26N/AN/A3/13/2025Q4 2024INDPIndaptus Therapeutics-$0.41-$0.38+$0.03-$0.38N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthASPCFAcerus PharmaceuticalsN/AN/AN/AN/AN/ABFRIBiofronteraN/AN/AN/AN/AN/AGNPXGenprexN/AN/AN/AN/AN/AINDPIndaptus TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioASPCFAcerus PharmaceuticalsN/A0.670.34BFRIBiofronteraN/A1.530.94GNPXGenprexN/A0.860.86INDPIndaptus TherapeuticsN/A3.423.42Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipASPCFAcerus PharmaceuticalsN/ABFRIBiofrontera10.08%GNPXGenprex14.05%INDPIndaptus Therapeutics7.06%Insider OwnershipCompanyInsider OwnershipASPCFAcerus PharmaceuticalsN/ABFRIBiofrontera0.21%GNPXGenprex8.47%INDPIndaptus Therapeutics29.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableASPCFAcerus Pharmaceuticals147.71 millionN/ANot OptionableBFRIBiofrontera709.45 million7.73 millionNo DataGNPXGenprex2024.15 million7.79 millionNo DataINDPIndaptus Therapeutics616.03 million9.96 millionNot OptionableASPCF, INDP, GNPX, and BFRI HeadlinesRecent News About These CompaniesIndaptus Therapeutics (INDP) to Release Quarterly Earnings on WednesdayMay 12 at 3:39 AM | americanbankingnews.comIndaptus Therapeutics Founder and Chief Scientific Officer Dr. Michael Newman Named Chair and Expert Speaker at 6th Annual Cytokine-Based Drug Development SummitMay 8, 2025 | globenewswire.comIndaptus Therapeutics, Inc. Common StockMarch 30, 2025 | fxempire.comIndaptus Therapeutics Chief Medical Officer Roger Waltzman, M.D., M.B.A. to Moderate Panel at CMO360 SummitMarch 25, 2025 | globenewswire.comIndaptus Therapeutics reports new data on Phase 1 trial of Decoy20March 21, 2025 | markets.businessinsider.comIndaptus Therapeutics Reports New Data Demonstrating Successful Broad Immune System Activation in Weekly Dosing Trial of Decoy20March 20, 2025 | globenewswire.comIndaptus Therapeutics Initiates Phase 1 Combination Study of Decoy20 with PD-1 Checkpoint Inhibitor TislelizumabMarch 18, 2025 | globenewswire.comIndaptus Therapeutics reports FY24 EPS ($1.61) vs ($1.83) last yearMarch 13, 2025 | markets.businessinsider.comIndaptus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Corporate UpdateMarch 13, 2025 | globenewswire.comRegistration Is Now Open For Tribe Public's Webinar Event “Keys To The Kingdom: Unlocking The Power Of Your Immune System” Featuring Indaptus Therapeutics' CEO On Monday, March 17, 2025March 12, 2025 | globenewswire.comIndaptus Therapeutics expands patent portfolio in China, Japan, IsraelMarch 4, 2025 | markets.businessinsider.comIndaptus Therapeutics Expands Patent Portfolio in China, Japan, and Israel, Strengthening its Intellectual Property for Infectious Disease and Cancer TreatmentsMarch 4, 2025 | globenewswire.comIndaptus Therapeutics’ Chief Scientific Officer Dr. Michael Newman to Present at the 10th Annual Innate Killer SummitFebruary 25, 2025 | markets.businessinsider.comIndaptus Therapeutics' Chief Scientific Officer Dr. Michael Newman to Present at the 10th Annual Innate Killer SummitFebruary 25, 2025 | globenewswire.comIndaptus Therapeutics files to sell 10M shares of common stock for holdersFebruary 13, 2025 | markets.businessinsider.comIndaptus Therapeutics expands cancer trial to CanadaFebruary 5, 2025 | msn.comIndaptus Therapeutics Receives Approval from Health Canada to Expand Clinical Trial of Decoy20February 5, 2025 | globenewswire.comIndaptus Therapeutics, Inc. Announces $2.25 Million Private Placement Priced At-The-Market Under Nasdaq RulesJanuary 13, 2025 | stockhouse.comIndaptus Therapeutics looks to raise $2.25M in private placementJanuary 13, 2025 | msn.comIndaptus Therapeutics announces anticipated milestones in 1H of 2025January 8, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeASPCF, INDP, GNPX, and BFRI Company DescriptionsAcerus Pharmaceuticals OTCMKTS:ASPCF$0.22 0.00 (0.00%) As of 07/21/2023Acerus Pharmaceuticals Corp. is a pharmaceutical company. The firm is focused on the commercialization and development of prescription products that improve patient experience, with a focus in the field of men's health. It focuses on therapeutics for urology, andrology, and endocrinology. Its products include Estrace and Natesto. The company was founded by Bruce D. Brydon, Rolf K. Reininghaus and Mark L. Thompson on September 9, 2008 and is headquartered in Mississauga, Canada.Biofrontera NASDAQ:BFRI$0.72 +0.04 (+5.32%) As of 04:00 PM EasternBiofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.Genprex NASDAQ:GNPX$0.28 +0.01 (+2.14%) As of 04:00 PM EasternGenprex, Inc., a clinical-stage gene therapy company, focuses on developing gene-based therapies for patients with cancer and diabetes in the United States. The company's lead product candidate is REQORSA (GPX-001), which is in preclinical trials to treat non-small cell lung cancer and small cell lung cancer; and GPX-002, which is in preclinical trials to treat type 1 and type 2 diabetes. Its product pipeline comprises Acclaim-1, which is in phase 2a clinical trial for the treatment of non-small cell lung cancer; Acclaim-2, which is in phase phase 1/2 clinical trial for the treatment of non-small cell lung cancer; and Acclaim-3, which is in phase 1/2 clinical trial for the treatment of small cell lung cancer. The company also develops ONC-001, REQORSA as a monotherapy, which is in phase 1 clinical trial to treat advance non-small cell lung cancer; and ONC-002, REQORSA with Tarceva, which is in phase 2 clinical trial to treat non-small cell lung cancer. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.Indaptus Therapeutics NASDAQ:INDP$0.44 +0.02 (+5.69%) As of 04:00 PM EasternIndaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas NVIDIA Stock Surges on Bullish News: How High Could It Climb? NuScale Power in Rebound Mode With Short-Squeeze a Possibility Why Amazon May Never Dip Below $200 Again eBay Nears Big Breakout: Time to Buy the Under-the-Radar Winner? Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for Long Why Boeing May Be Ready to Take Off After Latest Developments Goldman Sachs Warns of 20% Market Sell-Off: Are They Right? 3 Huge S&P 500 Winners From Trump Trade Deal & The Biggest Loser Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
